These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1948092)

  • 21. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers.
    Sié P; Albarede JL; Robert M; Bouloux C; Lansen J; Chigot C; Correll S; Thouvenot JP; Boneu B
    Thromb Haemost; 1986 Feb; 55(1):86-9. PubMed ID: 2422778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo release of anti-Xa clotting activity by a heparin analogue.
    Thomas DP; Barrowcliffe TW; Merton RE; Stocks J; Dawes J; Pepper DS
    Thromb Res; 1980 Mar; 17(6):831-40. PubMed ID: 6773178
    [No Abstract]   [Full Text] [Related]  

  • 25. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation.
    Leitner JM; Jilma B; Mayr FB; Cardona F; Spiel AO; Firbas C; Rathgen K; Stähle H; Schühly U; Graefe-Mody EU
    Clin Pharmacol Ther; 2007 Jun; 81(6):858-66. PubMed ID: 17410124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa.
    Graefe-Mody EU; Schühly U; Rathgen K; Stähle H; Leitner JM; Jilma B
    J Thromb Haemost; 2006 Jul; 4(7):1502-9. PubMed ID: 16839346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. I. Effects of heparin fractions.
    Schmitz-Huebner U; Balleisen L; Asbeck F; van de Loo J
    Thromb Haemost; 1981 Oct; 46(3):612-6. PubMed ID: 7031982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123.
    Moll S; Lindley C; Pescatore S; Morrison D; Tsuruta K; Mohri M; Serada M; Sata M; Shimizu H; Yamada K; White GC
    J Thromb Haemost; 2004 Oct; 2(10):1745-51. PubMed ID: 15456485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients.
    Palareti G; Legnani C; Bianchini B; Guazzaloca G; Maccaferri M; Marabini A; De Iaco P; Marcozzi S; Mancini L; Orlandi C
    Int Angiol; 1989; 8(1):47-52. PubMed ID: 2768958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
    McGlasson DL; Harroff HH; Sutton J; Dick E; Elston DM
    Clin Lab Sci; 2007; 20(2):99-105. PubMed ID: 17557708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacology of a new low molecular weight heparin (Alfa LMWH-Fluxum).
    Dettori AG; Tagliaferri A; Dall'Aglio E; Pini M
    Int Angiol; 1988; 7(3 Suppl):7-18. PubMed ID: 2850327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of heparin and its pharmacodynamic effect on plasma lipoprotein lipase activity and coagulation in healthy horses.
    McCann ME; Watson TD; Boudinot FD; Moore JN
    Am J Vet Res; 1995 Aug; 56(8):1070-4. PubMed ID: 8533979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man.
    Boneu B; Necciari J; Cariou R; Sié P; Gabaig AM; Kieffer G; Dickinson J; Lamond G; Moelker H; Mant T
    Thromb Haemost; 1995 Dec; 74(6):1468-73. PubMed ID: 8772222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated coagulation time in monitoring heparinized dogs.
    Green RA
    Am J Vet Res; 1980 Nov; 41(11):1793-7. PubMed ID: 7212408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.